Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

Dow:

Nasdaq:

S&P 500:

VTRS

$19.040.86%-0.165

시간 외 거래: 18.91-0.13 -0.66%

Viatris Inc (VTRS)

Date: O: H: L: C: Vol:

Viatris Inc 주식(VTRS)의 최신 뉴스

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats - Zacks Investment Research

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.

What US Small Cap Value Portfolio ETF (DFSV) Bought: Dick's Leads on Wednesday - Yahoo Finance

Form 4 Viatris Inc: David S. Simmons (Director) For: 30 September - Investing.com UK

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research

Viatris to Acquire Pacira in $1.65 Billion Deal - Contract Pharma

An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan

Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada

Pacira BioSciences jumps 44% after Viatris agre... - Pluang

Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com

Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com

Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart

Why Pacira BioSciences Skyrocketed Today - The Motley Fool

A $36.50-a-share cash deal would add a wholly owned subsidiary to Viatris (VTRS). - Stock Titan

Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com South Africa

Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom

Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc. - Ashurst Perkins Coie

Doubling up in pain: Viatris pays $1.65B, Pacira gets relief - BioWorld News

Viatris to acquire Pacira BioSciences for $1.65 billion - Investing.com

Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive

VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research

Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research

Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research

Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK

Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com Nigeria

Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com South Africa

Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com UK

Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research

Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research

More than 300,000 people took part in Forbes' employer survey; Viatris made the list. - Stock Titan

Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street

Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView

Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress

Viatris, Long Chau launch lipid disorder management campaign - VnExpress International

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha

VTRS - Finviz

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris gets 11% passive stake disclosed by FMR | VTRS SEC Filing - Form SCHEDULE 13G/A - Stock Titan

Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com

VTRS와(과) 유사한 종목

UTHR$598.720.87%

NBIX$146.100.19%

ELAN$23.060.77%

ALKS$45.340.07%